Who makes Dilaudid (hydromorphone) and who owns the brand? Dilaudid is a brand name for hydromorphone, an opioid pain medicine…. https://www.Drugchatter.com/chat/53035/who-owns-dilaudid-company/

What is the Chinese (CN) name for Ozempix? The provided information doesnt include any details about a product named… https://www.Drugchatter.com/chat/36985/ozempix-chinese-name/

Which Chinese pharmaceutical companies are investing in AI? A number of Chinese drugmakers have been putting money into… https://www.Drugchatter.com/chat/50765/chinese-pharmsutical-company-investing-in-ai/

Is Gleevec (imatinib) among the most expensive drugs? Gleevec (imatinib) is widely known as an expensive cancer medicine,… https://www.Drugchatter.com/chat/31710/is-gleevec-the-most-expensive-drug/

Branded generics vs. commodity generics: how brand trust wins market share
In pharma, generic used to mean one thing: the same active ingredient, the same molecule, the same outcome.
But the market has moved on.
Today, the real differentiator isnt just…

Pharma has a timing problemand its getting more expensive.
In the race to launch, the first patent filing isnt just a legal milestone. Its a commercial strategy. The companies that win market share increasingly treat IP like an operating system: built …

Dont Get Blind-Sided: The Critical Drug Patent Mistakes to Avoid in MA Due Diligence
Mergers and acquisitions in healthcare move fastuntil a single patent issue stops the deal cold.
In Massachusetts (MA) and beyond, acquirers often focus on clinical da…

Post-Approval Patents: The Hidden LOE Risk Map Pharma Teams MissUntil Its Too Late
In pharma, the real fight often doesnt start at approval. It starts after.
Once a drug is approved, the clock doesnt just tick on exclusivityit also ticks on a less visi…

Post-Approval Patents: The Hidden Loe Risk Map Pharma Cant Afford to Ignore
Most teams think the patent story ends at approval.
They shouldnt.
In the post-approval world, the real risk often hides in plain sight: patents that are filed, asserted, or st…

Beyond 20 Years: What Actually Determines a Drugs Market Exclusivity (and Why It Matters More Than You Think)
Most people hear 20 years and assume the clock is the whole story. Patent terms. Expiration dates. A clean countdown to generic entry.
But in …